Navigation Links
Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease
Date:11/10/2008

NOVATO, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that the Company has entered into an agreement with the Centre Hospitalier Universitaire d'Angers ("CHU d'Angers") of France to evaluate Raptor's proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in a Phase II clinical trial in patients with Huntington's Disease ("Huntington's"). CHU d'Angers has received a grant from the Programme Hospitalier de Recherche Clinique - National, a program under the French Ministry of Health, to fund the two-year, multi-center Phase II clinical trial in Huntington's patients. Under the terms of the agreement, Raptor will provide clinical supplies of DR Cysteamine for the trial.

In May 2008, the Office of Orphan Product Development at the U.S. Food and Drug Administration ("FDA") granted orphan drug designation to Raptor for cysteamine-based drugs, including DR Cysteamine, for the treatment of Huntington's.

Ted Daley, President of Raptor's Clinical Division, stated, "We look forward to collaborating with CHU d'Angers to evaluate DR Cysteamine in patients with Huntington's Disease. Our formation work with DR Cysteamine in conjunction with the CHU d'Angers studies in Huntington's fits our strategic plan to explore multiple potential indications for cysteamine and DR Cysteamine. Cysteamine has demonstrated neuroprotective effects in preclinical studies, and the planned Phase II study led by CHU d'Angers could confirm existing data regarding cysteamine's safety and potential efficacy in Huntington's."

Professor Dominique Bonneau, M.D., Ph.D. of CHU d'Angers, commented, "We are encouraged by the existing studies that indicate cysteamine's potential as a neuroprotectant for treating Huntington's, and we believe that Raptor's formulation could offer a better tolerated drug for this patient population. We are confident that this trial will enhance our
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Raptor Pharmaceuticals Provides Update on Targeting Platforms
2. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
3. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
4. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
5. Raptor Pharmaceuticals Provides Update of Product Programs
6. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
7. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
8. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
9. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
10. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
11. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... JORDAN, Utah , July 10, 2014  BC ... solutions, and MiE America , Inc., a leading ... have entered into a long-term agreement naming BC Technical ... the US. MiE and BC Technical ... strategic agreement to establish BC Technical as the service ...
(Date:7/10/2014)... -- CVS Caremark Corporation (NYSE: CVS ) today ... dividend of $0.275 (27.5 cents) per share on the corporation,s ... to holders of record on July 21, 2014. ... to helping people on their path to better health as ... States . Through the company,s more than 7,600 CVS/pharmacy ...
(Date:1/15/2014)... DUBLIN , Jan. 15, 2014  Research and Markets ... "Dental Consumables Market - Global Industry Analysis, Size, ... report to their offering. (Logo: ... products which are used on patients in order to ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
... SUNNYVALE, Calif. , June 3 Accuray ... the field of radiosurgery, today announced the installation of the ... of its acceptance as the world,s leading device for radiosurgery. ... in the United Kingdom , the first hospital operated ...
... , June 3 Perrigo Company (Nasdaq: PRGO ... the U.S. Food and Drug Administration for its abbreviated new drug ... generic to Monistat® -1 Combination Pack. Perrigo expects to begin shipping ... , ...
Cached Medicine Technology:Accuray Installs 200th CyberKnife Robotic Radiosurgery System 2Accuray Installs 200th CyberKnife Robotic Radiosurgery System 3Accuray Installs 200th CyberKnife Robotic Radiosurgery System 4Accuray Installs 200th CyberKnife Robotic Radiosurgery System 5Perrigo Announces FDA Final Approval for Miconazole 2Perrigo Announces FDA Final Approval for Miconazole 3
(Date:7/11/2014)... to understand the best available treatment for patients, from ... less costly for taxpayers than the existing clinical trial ... van Staa, carried out while he was a member ... is now based at The University of Manchester,s Health ... ( HTA ) today (Friday 11 July) looked at ...
(Date:7/11/2014)... Steven Reinberg HealthDay ... Stress, hostility and depression may increase the risk for stroke, ... seemed to raise the risk of a stroke or ... found that stress apparently raised stroke or TIA risk by ... A TIA is a mini-stroke caused by a temporary blockage ...
(Date:7/11/2014)... Aarhus University has revealed that people who have grown ... as likely as their urban counterparts to develop the ... disease. The study findings have recently been published in ... is extremely exciting that we can now see that ... diseases appear to depend on the environment we are ...
(Date:7/11/2014)... 2014 As reported by Forbes in ... Are Genetics To Blame (6/30), Indino Downey has reportedly ... paraphernalia to smoke it with. His father, well-known actor ... son inherited from him may have something to do ... news during the 1980s and 1990s for substance abuse ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Having experienced mental ... a member of mental hospital staff, Roger Grainger gives readers ... professionals in his new book, “You Never Get Out.” , ... in the United Kingdom will experience some kind of mental ... “Society still needs to take a look at the way ...
Breaking Medicine News(10 mins):Health News:Better use of electronic health records makes clinical trials less expensive 2Health News:Stress, Depression May Boost Stroke Risk, Study Finds 2Health News:Stress, Depression May Boost Stroke Risk, Study Finds 3Health News:Growing up on a livestock farm halves the risk of inflammatory bowel diseases 2Health News:Roberty Downey's Son Arrested For Cocaine 2Health News:Psychiatric Hospital Patient and Registered Psychologist Explores Mental Health and Therapy in New Book "You Never Get Out" 2
... (TORONTO Nov. 28, 2011) A second, larger clinical ... Hospital (PMH) has again proven that comparing a new biopsy ... cancer can dictate a change in treatment. The ... Journal of Clinical Oncology . Principal investigator Dr. ...
... areas in the brain,s left hemisphere enable us to understand ... those areas divvy up the highly complex processes necessary to ... within the last 10 years have revealed that highly complex ... particular regions of the cerebral cortex, but also on the ...
... MONDAY, Nov. 28 (HealthDay News) -- Most U.S. heart ... hospital for a procedure to open narrowed or blocked ... 30 minutes or less, new research shows. The ... procedures such as balloon angioplasty or stent placement (called ...
... Academic institutions in Sweden are among the quickest to adopt ... Experiments ( JoVE ), with over 35 percent of ... for this phenomenon is that Swedes are among the fastest ... think we are a very curious people and interested in ...
... between breakfast and lunch lose less weight compared to those ... led by researchers at Fred Hutchinson Cancer Research Center., The ... Ph.D., a member of the Hutchinson Center,s Public Health Sciences ... in the December issue of the Journal of the ...
... a second primary cancer of the same type, according to ... Association Journal ) (pre-embargo link only) http://www.cmaj.ca/site/embargo/cmaj110167.pdf , whereas ... was only slightly elevated. Danish researchers looked at data ... people) from 1980 to 2007 to determine whether the risk ...
Cached Medicine News:Health News:New study shows biopsy of recurrent breast cancer can alter treatment 2Health News:How the brain strings words into sentences 2Health News:How the brain strings words into sentences 3Health News:How the brain strings words into sentences 4Health News:Lengthy Hospital Transfers May Hamper Heart Attack Care 2Health News:Swedish people are quick to adopt JoVE, a video journal for biomedical sciences 2Health News:Mid-morning snacking may sabotage weight-loss efforts 2Health News:Mid-morning snacking may sabotage weight-loss efforts 3Health News:Risk of second cancer in cancer survivors mainly confined to the same cancer type as the first 2Health News:Risk of second cancer in cancer survivors mainly confined to the same cancer type as the first 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... used in the ARED study, as well ... which suggested no AMD disease progression in ... period. Macula Complete also contains efficacious amounts ... support the mitochondria, as well as to ...
... MacularProtect delivers levels of ... vision and macular health in ... by The National Eye Institute. ... of lutein, an antioxidant found ...
... is a scientifically advanced nutritional formulation ... and full body health. MacularProtect Complete ... trial and other advanced research. It ... provides a broad foundation of antioxidants, ...
Medicine Products: